The Valley Desk

NCT00569127 · Interventional trial

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Overall registry status Active not recruiting

Phase 3

Conditions Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov